Posts Tagged: Paul Santerre
Completed her Ph.D. in Dr. Paul Santerre’s lab in 2019, Dr. Meghan Wright always had a passion for entrepreneurship, business, and science. After graduating, Meghan interned briefly with the life sciences investment firm Bloom Burton & Co. as a consultant before joining Shift Health, a life sciences and healthcare strategy consulting firm located in Toronto. Now Meghan is working on projects across a wide range of areas – from the private sector to academia, to help transform healthcare.
International team awarded grant to investigate immune-modulating biomaterials for endometrium tissue engineering
January 11, 2022 | A new grant will look at the use of biomaterials for endometrium tissue engineering. The￥2,000,000, (approximately C$400,000) grant was awarded to the Faculty’s professor Paul Santerre and his former PhD student, Xiaoqing Zhang, now a faculty member at Binzhou Medical University in China, who are co-PIs on the grant.
November 11, 2021 | In the 4th volume of Nature’s Communications Biology, researchers at TBEP published an important study that can reshape the way we engineer new blood vessels for patients who need them.
May 26, 2021 | An innovative biomaterial discovery by researchers at the University of Toronto in collaboration with Ripple Therapeutics Inc., has established a method that yields better control over drug release profiles in implants and has the potential to disrupt the classical drug delivery market.
‘Our very first biotech win’: How U of T’s discovery of insulin made it a research and innovation powerhouse
November 4, 2020 | Paul Santerre, a professor in the Faculty of Dentistry and the Institute of Biomedical Engineering, says the extent of progress on diabetes and insulin will partly depend on how well research breakthroughs from scholars like Brubaker can be married with efforts at commercialization and innovation.
March 25, 2020 | Paul Santerre receives lifetime achievement award from Canadian Biomaterials Society
October 25, 2019 | Interface Biologics's (IBI) antithrombogenic additive have been used in a new line of FDA-approved "breakthrough" dialysis products made by IBI's partner, Fresenius Medical Care.
September 5, 2019 | Multidisciplinary team awarded five year, $1M project grant to develop a new filling material
This U of T Engineering innovation makes implants safer, and is attracting new investment to Toronto
September 3, 2019 | Global chemical company Evonik will maintain presence in Toronto after acquiring part of U of T spinoff Interface Biologics, Inc.
May 21, 2019 | Cohesys, a biomedical device startup that makes biodegradable ‘bone tape’ to help heal facial fractures, recently took home US$20,000 at an international competition.
Showing 1 - 10 of 30 results